Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

PARP inhibitors are being explored clinically in several other types of cancer that exhibit HRD. A few examples are presented here, but additional trials are continually being added to clinical trial registries.

Endometrial Cancer

Niraparib, olaparib and rucaparib are all being investigated in advanced endometrial cancer.

In the monotherapy setting, a phase II study is investigating niraparib in patients with recurrent endometrial cancer, regardless of PTEN status (NCT03016338).

In the maintenance setting, both olaparib and rucaparib are being explored following treatment with chemotherapy in patients with metastatic and/ or recurrent endometrial cancer. A randomised phase II study is assessing the benefit of rucaparib versus placebo after 1-2 prior lines of therapy (NCT03617679), and a randomized, double-blinded study (UTOLA; NCT03745950) is underway of olaparib versus placebo. Results from these trials are expected in 2022 or beyond.

Urothelial Cancer

Rucaparib monotherapy is being assessed in patients with locally-advanced unresectable or metastatic urothelial carcinoma (ATLAS trial; NCT03397394).

Gastroesophageal Cancer

The phase II PLATFORM trial (NCT02678182) is studying several maintenance treatments, including rucaparib, for patients with locally advanced or metastatic HER-2 positive or HER-2 negative gastroesophageal cancer following completion of standard first-line chemotherapy.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings